article thumbnail

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that I.V. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

article thumbnail

Differences in heart failure with preserved ejection fraction management between care providers: an international survey

European Journal of Heart Failure

Differences in heart failure with preserved ejection fraction (HFpEF) management across medical specialties. Methods and results An independent web-based survey was distributed globally between May and July 2023. A large majority of HFpEF patients are cared by non-cardiologists.

article thumbnail

Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF

Circulation: Heart Failure

Circulation: Heart Failure, Volume 16, Issue 11 , Page e010633, November 1, 2023. BACKGROUND:Heart failure with preserved ejection fraction is associated with significant functional limitations, yet treatments for improving exercise performance have been elusive.

article thumbnail

Atrial fibrillation and risk of adverse outcomes in heart failure with reduced, mildly reduced, and preserved ejection fraction: A systematic review and meta?analysis

Journal of Cardiovascular Electrophysiology

Contemporary classification of HF categorizes it into HF with reduced ejection fraction (HFrEF), HF with mildly reduced ejection fraction (HFmrEF), and HF with preserved ejection fraction (HFpEF). A systematic search of PubMed, EMBASE, and Cochrane Library databases until February 28, 2023.

article thumbnail

Analysis of INPEFA (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology

DAIC

For more information: www.lexpharma.com Related content: New Post-Hoc Analysis of Pooled Phase 3 Data Shows That Inpefa (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association AHA 2023 Scientific (..)

article thumbnail

REBALANCE-HF: Splanchnic Nerve Ablation For Volume Redistribution in HFpEF

American College of Cardiology

Splanchnic ablation for volume management (SAVM) in heart failure with preserved ejection fraction (HFpEF) was discussed as a late-breaking trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023 in Cleveland, Ohio.

article thumbnail

Corrigendum to ‘Objectively Measured Night-Time Sleep Efficiency and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction’ [American Journal of Cardiology 208 (2023) 124-125]

The American Journal of Cardiology

Publication date: Available online 13 April 2024 Source: The American Journal of Cardiology Author(s): Syed Imran Ahmed, Jonathan Kenyon, Hayley E. Billingsley, Hannah Salmons, Natalie J. Bohmke, Roshanak Markley, Antonio Abbate, Danielle L. Kirkman, Youngdeok Kim, Salvatore Carbone